3,158 Shares in iShares Biotechnology ETF $IBB Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC bought a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the fourth quarter, Holdings Channel reports. The fund bought 3,158 shares of the financial services provider’s stock, valued at approximately $534,000.

Other large investors have also recently bought and sold shares of the company. Basepoint Wealth LLC bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth about $26,000. Cary Street Partners Financial LLC bought a new position in shares of iShares Biotechnology ETF in the fourth quarter valued at approximately $29,000. Darwin Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF in the second quarter valued at approximately $25,000. Caitlin John LLC acquired a new position in shares of iShares Biotechnology ETF during the fourth quarter valued at approximately $34,000. Finally, Cornerstone Planning Group LLC acquired a new position in shares of iShares Biotechnology ETF during the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

Get iShares Biotechnology ETF alerts:

iShares Biotechnology ETF Price Performance

Shares of NASDAQ:IBB opened at $189.51 on Friday. iShares Biotechnology ETF has a 12 month low of $128.84 and a 12 month high of $199.05. The stock’s 50 day moving average price is $177.39 and its 200 day moving average price is $173.28.

iShares Biotechnology ETF Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Stockholders of record on Monday, June 15th were given a dividend of $0.0238 per share. The ex-dividend date was Monday, June 15th. This represents a $0.10 annualized dividend and a dividend yield of 0.1%.

iShares Biotechnology ETF Company Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Articles

• Five stocks we like better than iShares Biotechnology ETF
• Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
• Revving Up Returns: Big Banks Race Through the Rate Plateau
• Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
• Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.